Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

"Other" biologics included abatacept (Orencia), rituximab (Rituxan), sarilumab (Kevzara), and tocilizumab (Actemra). TNF inhibitors used in JAK-pot registries included adalimumab, etanercept ...

However, specific combinations such as abatacept with Janus kinase (JAK) inhibitors may be associated with increased risks. Researchers conducted an observational study using the health data ...

Biological and targeted synthetic DMARDs were split into five classes: TNF inhibitors, interleukin (IL)-6 inhibitors, JAK inhibitors, rituximab (Rituxan, Genentech) and abatacept (Orencia ...

During his tenure at BMS, Dr. Banerjee served as the global lead for mid- to late-stage clinical development of Sotyktu (deucravacitinib), Orencia (abatacept) and clazakizumab (anti-IL-6 antibody) for ...

Abatacept was not associated with an increased risk for malignancy in patients with rheumatoid arthritis or psoriatic arthritis based on clinical trial data, though observational data differed. Study ...

By contrast, the risk of withdrawal from abatacept, etanercept or rituximab therapy did not differ from control (ORs 0.8–1.3). Regarding withdrawal due to AEs, the NNT for harm amounted to ...

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies ...

These medications are Kineret (anakinra) or Orencia (abatacept). If you’re using Kineret or Orencia, your doctor will likely recommend switching one of your medications. This way, you’re not ...